Healthcare , Financials Author：Jizhen Huang Apr 14, 2022 11:03 PM (GMT+8)

Founded in 2017, Rigen Biotech is dedicated to the development, production, sales and testing services of individual molecular diagnosis. A specialist in thyroid cancer, Rigen Biotech has come up with integrated solutions for the entire thyroid cancer diagnosis and treatment cycle from preoperative sampling to postoperative monitoring.

In vitro diagnosis, medical examination, detection reagent

Rigen Biotech (Chinese: 睿璟生物) recently announced the completion of a CNY 100 million (USD 16 million) financing round. This round of funding was led by BioTrack Capital, followed by Guotai Junan Innovation Investment and Rencent Capital.

Prior to this round, Rigen Biotech has closed a Series A financing round, led by Oriza Capital and backed by Zhen Fund and Prosperico Ventures. The proceeds will be utilized to facilitate clinical pipelines, enhance scientific discovery and proof-of-concept, and advance commercialization process.

Rigen Biotech has developed a series of assays such as thyroid biopsy needles, multi-gene qPCR and NGS sequencing, Thyroscan® thyroid nodule classifier (benign/malignant), and postoperative recurrence monitoring. Verified by tens of thousands of clinical samples, Rigen Biotech’s preoperative multi-gene qPCR and NGS assays have entered the clinical registration phase.

Thyroscan® thyroid nodule classifier, benchmarked with Thyroseq®, is committed to becoming the ultimate solution for molecular diagnosis of thyroid nodules in China. To date, Thyroscan® is undergoing the only prospective clinical trial in China. Thyroscan® established a machine learning algorithm through the combination of multiple loci and modules to achieve precision diagnosis of preoperative thyroid nodules, to construct risk stratification in prognosis and to guide postoperative prescription.

Hong Jiedong, CEO of Rigen Biotech, claimed that the company is committed to becoming the leader in molecular diagnosis in the area of thyroid cancer. “Rigen is devoted to optimizing medical resources and improving the life quality of patients. We are currently building an ecosystem for the diagnosis of thyroid diseases, but our path leads to the diagnosis of various diseases,” said Hong.

Rigen Biotech’s competitors include AmoyDx (Chinese: 艾德生物, SZ:300685), BGI(Chinese:华大基因) and Dian Diagnostics (Chinese: 迪安诊断, SHE:300244).